Cover: Implementing the End-Stage Renal Disease Program of Medicare

Implementing the End-Stage Renal Disease Program of Medicare

Published 1980

by Richard A. Rettig, Ellen L. Marks


Download eBook for Free

FormatFile SizeNotes
PDF file 9.1 MB

Use Adobe Acrobat Reader version 10 or higher for the best experience.


Purchase Print Copy

 Format Price
Add to Cart Paperback271 pages $55.00

Analyzes the implementation of the End-Stage Renal Disease (ESRD) program of Medicare. Section 299I of Public Law 92-603, October 30, 1972, extends Medicare coverage to over 90 percent of Americans if they have permanent kidney failure and require dialysis or transplantation to live. The program had 11,000 beneficiaries on July 1, 1973; average annual enrollment for 1979 was 56,000 patients; and the patient population is projected to grow to 90,000 by 1995. ESRD benefit payments in 1974 were $283 million; they are estimated at $1.2 billion for 1979; and now exceed 4 percent of all Medicare expenditures. The report analyzes program implementation in relation to the administrative system, the stages of planning and operations, and the substance of reimbursement and medical issues.

This report is part of the RAND report series. The report was a product of RAND from 1948 to 1993 that represented the principal publication documenting and transmitting RAND's major research findings and final research.

This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.